Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker
Status
Conditions
Treatments
Details and patient eligibility
About
Lung cancer is the number one cancer killer in the USA. Early stage lung cancer is asymptomatic. Most patients with lung cancer are usually symptomatic at diagnosis and already have advanced stage disease. Low dose CT screening (LDCT) for high risk individuals has recently been shown to decrease lung cancer mortality by 20%. However, 4 out of 5 lung cancer deaths are not prevented with LDCT screening alone.
Full description
In this trial, the addition of a blood biomarker test is being combined with early LDCT to determine if screening with combination may result in detection of more lung cancer at an earlier stage of disease.The study will also assess if the blood test is able to detect lung cancers in high risk individuals when the LDCT is negative for cancer. There will be health-economic costs included in the final analysis of study data.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Smokers or former smokers
- At least 20 pack year history of smoking
- Ages 50 - 75
Exclusion criteria
- Had a CT scan of chest within last 24 months
- History of any cancer within 10 yrs (except skin cancer or cervical cancer)
- A serious illness that decreases life expectancy to less than 5 years
- Any current use of Oxygen
- Uncontrolled congestive heart failure or cardiac arrhythmia that would prevent surgery for a lung lesion
- Severe COPD or dyspnea that would prevent lung surgery or stereotactic body radiotherapy
Trial design
Primary purpose
Allocation
Interventional model
Masking
1,361 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal